Halozyme Therapeutics, Inc. (HALO) Stock
Fundamentals
Recent news

Why Women-Run Companies Deserve a Place in Your Portfolio
Why Women-Run Companies Deserve a Place in Your Portfolio
HALO

Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
HALO

Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?
Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?
HALO

3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
HALO
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $1.69 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

Why Women-Run Companies Deserve a Place in Your Portfolio
Why Women-Run Companies Deserve a Place in Your Portfolio
HALO

Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
HALO

Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?
Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?
HALO

3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
HALO

4 Value Stocks to Buy as Oil Surge Fuels Fed Rate Hike Fears
4 Value Stocks to Buy as Oil Surge Fuels Fed Rate Hike Fears
HALO

4 Best PEG Value Stocks to Buy Now for Strong Growth & Return
4 Best PEG Value Stocks to Buy Now for Strong Growth & Return
HALO

Record Revenue Growth Boosts Halozyme Shares
Record Revenue Growth Boosts Halozyme Shares
HALO

4 High-Growth GARP Stocks With Discounted PEG Ratios for 2026
4 High-Growth GARP Stocks With Discounted PEG Ratios for 2026
HALO

Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"
Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"
HALO

Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice
Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice
HALO
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. | President, CEO & Director | 1963 |
| Mr. Mark Snyder Esq. | Executive VP, General Counsel, Chief Compliance Officer & Corporate Secretary | 1967 |
| Mr. Darren Snellgrove | Senior VP & CFO | — |
| Mr. Brian Sweeney | Chief Human Resources Officer | 1964 |
| Mr. David A. Ramsay MBA | President of Drug Delivery | 1965 |
| Dr. Christopher Wahl M.B.A., M.D. | Chief Scientific Officer | — |
| Dr. Charles P. Theuer M.D., Ph.D. | Chief Medical Officer | 1964 |
| Mr. Paul Spence | Chief Commercial Officer | 1969 |
| Mr. Rhys de Callier | Chief Strategy Officer | — |
| Mr. Chase Coffman Ph.D. | President of Hypercon | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
5 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +2.6 | -6.6 | -15.8 | +25.0 | ||||||||
| 2022 | -15.7 | +0.9 | +11.9 | -4.1 | +12.6 | -3.1 | +9.9 | -16.1 | -2.6 | +19.3 | +18.6 | -0.9 |
| 2023 | -6.1 | -8.0 | -19.8 | -17.1 | -0.6 | +11.0 | +16.5 | +0.7 | -10.8 | -10.1 | +15.2 | -6.9 |
| 2024 | -9.5 | +16.2 | -1.0 | -7.8 | +12.7 | +16.2 | +6.2 | +16.0 | -6.5 | -10.7 | -15.7 | -1.6 |
| 2025 | +18.0 | +5.1 | +10.1 | -0.7 | -6.6 | -6.5 | +13.3 | +23.9 | +0.0 | -13.0 | +7.9 | -1.2 |
| 2026 | +2.0 | -6.6 | -7.5 | -2.7 | +4.0 | +14.9 | +7.2 | +29.4 | +5.7 |



